Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2012/11/003145
CTRI/2012/11/003145
Recruiting
Phase 2

A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

ovaBay Pharmaceutical Inc0 sites440 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
ovaBay Pharmaceutical Inc
Enrollment
440
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ovaBay Pharmaceutical Inc

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects must be \>\= 18 years of age and \<\= 65 years of age
  • •2\. At least 1 eye (and in that same eye) must have onset and development of ocular symptoms and/or signs of conjunctivitis \<\= 3 days prior to enrollment (Day 1\)
  • •3\. Females who are not pregnant and are not lactating.
  • •4\. Other inclusion criteria per protocol.

Exclusion Criteria

  • •1\.Presence of subepithelial infiltrates (SEIs) at the Day 1 visit in either eye.
  • •2\.Suspected bacterial, fungal, herpes, Chlamydia or Acanthamoeba co\-infection, based on clinical observation.
  • •3\.Subjects with ocular condition(s) that may interfere with the conduct of the study as outlined in the protocol.
  • •4\.Other exclusion criteria per protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Clinical Trial to study the effects of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral ConjunctivitisAdenoviral Conjunctivitis
SLCTR/2013/026ovaBay Pharmaceutical, Inc
Active, not recruiting
Phase 1
A randomized multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs. a tacrolimus-based control regimen in de novo liver transplant recipients.
EUCTR2007-001776-36-GBovartis Pharma Services AG
Active, not recruiting
Not Applicable
Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens(high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disease patients who have not responded to previous treatment with low dose imiglucerase - NDGAUCHER diseaseMedDRA version: 9.1Level: LLTClassification code 10018048Term: Gaucher's disease
EUCTR2007-005516-61-ITISTITUTO GIANNINA GASLINI
Recruiting
Not Applicable
A multicenter observational study on the efficacy and safety of systemic therapy for hepatocellular carcinoma
JPRN-UMIN000053532Kyoto University750
Recruiting
Not Applicable
A Multicenter Prospective Study on the Efficacy of Small Intestinal Capsule Endoscopy in Hemodialysis Patients
JPRN-UMIN000041904Keio university school of medicine500